About
About
Contact Us
Pipeline
Pipeline
Sirexatamab (DKN-01) Programs
Colorectal Cancer
Gastric Cancer
Endometrial Cancer
Prostate Cancer
Lung Cancer
FL-501 Program
Science
Science
DKK1
Sirexatamab (DKN-01)
GDF-15
Patients
Patients
Expanded access
Careers
Investors
Investors
Stock Information
News Releases
Presentations & Events
Financial Information
Information Request
Cypherpunk
Non-Small Cell Lung Cancer
sirexatamab (DKN-01)
Sirexatamab (DKN-01) in
lung cancer
Posters for the
lung cancer
indication
Phase 1 study evaluating the safety and efficacy of DKN-01, an investigational monoclonal antibody (Mab) in patients (pts) with advanced non-small cell lung cancer (ASCO 2014)
